Insulet Corporation $PODD Stock Holdings Cut by Candriam S.C.A.

Candriam S.C.A. cut its position in shares of Insulet Corporation (NASDAQ:PODD) by 31.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 45,769 shares of the medical instruments supplier’s stock after selling 20,733 shares during the quarter. Candriam S.C.A.’s holdings in Insulet were worth $9,604,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of PODD. Larson Financial Group LLC boosted its stake in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in Insulet in the fourth quarter worth about $26,000. Elyxium Wealth LLC bought a new stake in Insulet in the fourth quarter worth about $28,000. DV Equities LLC acquired a new stake in Insulet in the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. acquired a new stake in Insulet in the 4th quarter valued at about $29,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Stifel kept a buy rating on PODD, although it lowered its price target from $250 to $225, suggesting the stock still has meaningful upside despite recent volatility. Benzinga reference
• Neutral Sentiment: Insulet also appeared in a positive-style growth note and an article discussing the stock’s valuation after a sharp decline, but these pieces did not provide fresh company-specific catalysts. Yahoo Finance reference
• Neutral Sentiment: Short-interest data showed no reported short interest as of July 10, so it does not currently signal a meaningful bearish positioning change.
• Negative Sentiment: Several law firms announced or promoted class-action lawsuits against Insulet over alleged securities fraud and Omnipod safety disclosures, which can create investor uncertainty and pressure the stock. PR Newswire reference

Insulet Stock Performance

NASDAQ:PODD opened at $161.28 on Monday. The stock has a fifty day simple moving average of $152.93 and a 200 day simple moving average of $210.77. The firm has a market capitalization of $11.17 billion, a price-to-earnings ratio of 37.51, a price-to-earnings-growth ratio of 1.12 and a beta of 1.11. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter in the previous year, the company earned $1.02 EPS. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Sell-side analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.36% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Jefferies Financial Group lowered their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. UBS Group set a $219.00 target price on shares of Insulet in a research note on Thursday, June 11th. Piper Sandler reduced their target price on shares of Insulet from $360.00 to $210.00 in a report on Wednesday, May 6th. Citigroup lifted their price target on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Barclays decreased their price target on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $237.08.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.